On August 6, Tectonic Therapeutic (NASDAQ:TECX) reported second quarter results built around two clinical wins rather than sales figures, since this is a clinical stage biotech company with no products on the market yet. The headline news is that both of its lead programs hit their scheduled marks this year, and the company says it has enough cash to keep funding them into 2029. For a company still years from a possible approval, that mix of progress and runway is what investors are watching most closely.
Two Programs Hit Their Marks
The company completed enrollment for its APEX Phase 2 trial of TX45 in patients with pulmonary hypertension tied to heart failure with preserved ejection fraction in June, bringing in 191 patients across 14 countries. Tectonic built the trial to skew toward the sicker CpcPH subgroup with a pulmonary vascular resistance above 3 Wood Units, and 137 of the 191 patients, about 70% of the total, met that bar exactly as planned. In July, an independent data monitoring committee reviewed unblinded safety and efficacy data covering roughly 80% of expected patient exposure and recommended the trial continue without any changes, a vote of confidence from outside reviewers with access to real trial data. Topline results are expected in early Q1 2027.
The second program is moving just as fast. Tectonic finished dosing all six single-dose cohorts of TX2100 in healthy volunteers in July, part of a Phase 1a trial testing the antibody as a treatment for hereditary hemorrhagic telangiectasia, a rare bleeding disorder with no approved therapies. Topline results are due by the end of Q3 2026, and if the safety and pharmacokinetic data hold up, the company plans to push TX2100 into a Phase 1b trial in HHT patients who depend on blood transfusions or iron infusions and a Phase 2 trial in moderate to severe patients, both starting in early 2027.
Losses Widen As Bills Grow
None of this comes cheap. Tectonic posted a net loss of $22.3 million for the quarter ended June 30, 2026, up from $20 million a year earlier. R&D spending rose to $18 million from $17.2 million, driven by contract research costs tied to the TX45 trials and a larger headcount, while G&A costs climbed to $6.2 million from $5.2 million on higher stock-based compensation. Cash and cash equivalents dropped to $227.1 million by the end of June, down from $236.9 million three months earlier, even after the company raised roughly $11.7 million through an at-the-market stock offering during the quarter.
